Fig. 8. Antitumor activity of LCH in oxaliplatin (Ox)-sensitive and Ox-resistant CRC cells.

Biomolecules & Therapeutics 2023;31:661~673 https://doi.org/10.4062/biomolther.2023.155

© Biomolecules & Therapeutics